⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz Michael J. Shamblott Andrew S. Brohl Amod A. Sarnaik Zeynep Eroglu Nikhil I. Khushalani Christopher W. Dukes Alejandra Chamizo Marina Bastawrous Edward T. Garcia Ashraf Dehlawi Pei-Ling Chen Deanryan B. De Aquino Vernon K. Sondak Ahmad A. Tarhini Youngchul Kim Patricia Lawman Shari Pilon‐Thomas

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplemental Figure 8: Nucleic Acid Sequence of pAc/emm55 Construct with Amino Acid Translation

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Markowitz et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574c93 https://doi.org/10.1158/1535-7163.26423953

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
2Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
3Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
4Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
5Data from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
6First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024 · 9 citations
7Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
8Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024